IV Disposables Market Report

The rising prevalence of diseases such as neurological diseases, gastrointestinal diseases, and cancer, in which IV fluids are administered to patients, is a major driver driving market expansion. According to the World Health Organisation, diarrhoeal disease is the second largest cause of mortality in children under the age of five. For instance, an estimated 1.22 million young children die each year from pneumonia or diarrhea, which equates to more than 140 children dying per hour or 3,350 deaths every day. To manage diarrheal conditions effective and fast treatment is required. IV bag fluids are used to avoid dehydration, regulate blood pressure, or provide patients medications or nutrients if they are unable to eat, which is ideal for fast stabilisation when the body's minerals are lost due to diarrhea.

Infusion pumps accounted for the largest share of the global market. Infusion pumps provide patients with precise and regulated delivery of fluids, medicines, and nutrients. They are intended to administer these compounds at precise rates and quantities, assuring dose precision and consistency. In many medical conditions, such as chemotherapy, critical care, and pain management, this level of accuracy is crucial. Intravenous disposables, such as specialised connections and pressure sensors, are intended to operate with infusion pumps to provide safe and precise fluid and medicine administration. Overall, due to their exact and regulated administration of fluids and drugs, better safety features, and compatibility with various IV disposables, infusion pumps are a frequently utilised treatment option for IV disposables.

The high price of IV disposable equipment might limit its use in some healthcare facilities, particularly those with limited budgets. Healthcare providers may choose less expensive options, such as oral drugs or subcutaneous injections, limiting the growth of the IV disposables equipment market. Product recalls can have an impact on the Intravenous disposables equipment industry in the United States by lowering revenue, increasing regulatory attention, raising patient safety concerns, and boosting litigation expenses. This might have an effect on the overall growth of the IV disposables equipment industry. Alternative treatments may be less expensive for healthcare providers and insurance companies to implement as they involve fewer equipment and human resources. This can restrict the adoption of IV disposable equipment and have an impact on the market's overall growth. These factors are projected to stifle market revenue growth throughout the forecast period.

Major industry leaders utilize strategies that focus on launching new products, merging with competitors, and purchasing companies to grow their customer base and enhance their range of products. In July 2024, Nipro Medical Corporation, a leading force in the healthcare and medical device sector, unveiled plans to establish its inaugural North American manufacturing center in Greenville, North Carolina. This strategic move will create 232 new positions and serve as the U.S. headquarters for Nipro. The 550,000-square-foot facility will feature a medical training center and customer service hub, significantly boosting the company’s capacity to deliver advanced IV disposable and other high-end medical devices to the North American market.

In December 2023, Baxter International Inc., a leader in infusion technologies, successfully completed the initial phase of its pioneering IV bag recycling pilot with Northwestern Medicine. This innovative program has diverted over 12,000 pounds of PVC IV bag waste from landfills, recycling it into products like industrial mats and protective edging. The initiative, marking a U.S. first, underscores Baxter's commitment to sustainable practices and sets a new standard in waste management for hospital settings.

The ageing population, the need for enhanced patient care and safety, the growth of healthcare infrastructure, and the increased emphasis on infection control are driving demand for IV disposable in the United States. According to the American Cancer Society, in 2024, an estimated 2,001,140 new cancer cases are expected, translating to roughly 5,480 diagnoses daily. Among these, about 56,500 will be ductal carcinoma in situ in women, while 99,700 cases will involve melanoma in situ of the skin. According to the NCBI, it is projected that there will be 28.4 million cases of cancer worldwide in 2040. Such factors led to the acquisitions, mergers, and the launch of new products by key players that all contribute to market expansion in this region. For instance, in February 2022, B. Braun Medical, a German infusion therapy business, received FDA clearance to commence operations at its new IV saline solution production plant in Daytona Beach, Florida. The plant, which is part of the company's US$ 1 billion deal to invest in its U.S. production and supply chain to solve IV fluid shortages, is expected to manufacture 0.9% sodium chloride for injection. As a result of the aforementioned factors, North America is projected to grow throughout the market's forecast period.